Not checkedNot checked for notices yet.
Decitabine for Acute Myeloid Leukemia in a Patient Undergoing Hemodialysis
T.V. Kourelis, M.N. Moustakakis, R. Silk and 3 more
European Journal of Inflammation · 2011
doi:10.1177/1721727x1100900310 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Treatment of patients with Acute Myeloid Leukemia (AML) undergoing hemodialysis is especially challenging since there are no specific management guidelines for the administration of cytotoxic agents in these patients. Well established chemotherapy protocols may be unsuitable in such cases because of altered drug pharmacokinetics, increased risk for complications, and underlying co-morbidities. In addition, these patients are at an increased risk for complications such as tumor lysis syndrome. Herein, we report the first use of decitabine in a patient on hemodialysis. He presented with a new diagnosis of AML and achieved hematologic remission following the use of induction chemotherapy and maintenance decitabine.
Abstract licence: CC BY-NC
References11
11 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.